Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.

× No keyword cloud information.

19 in total

1. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.

Authors: Jenny J Kim; Susan A J Vaziri; Brian I Rini; Paul Elson; Jorge A Garcia; Robert Wirka; Robert Dreicer; Mahrukh K Ganapathi; Ram Ganapathi
Journal: Cancer Date: 2011-08-31 Impact factor: 6.860

2. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.

Authors: Kriti Mittal; Henry Koon; Paul Elson; Pierre Triozzi; Afshin Dowlati; Helen Chen; Ernest C Borden; Brian I Rini
Journal: Cancer Biol Ther Date: 2014-05-19 Impact factor: 4.742

3. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.

Authors: Justine Yang Bruce; Jill M Kolesar; Hans Hammers; Mark N Stein; Lakeesha Carmichael; Jens Eickhoff; Susan A Johnston; Kimberly A Binger; Jennifer L Heideman; Scott B Perlman; Robert Jeraj; Glenn Liu
Journal: Cancer Chemother Pharmacol Date: 2014-01-12 Impact factor: 3.333

4. A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.

Authors: Sumanta Kumar Pal; Nicholas J Vogelzang
Journal: Clin Genitourin Cancer Date: 2012-12-29 Impact factor: 2.872

5. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

Authors: Keith T Flaherty; Judith B Manola; Michael Pins; David F McDermott; Michael B Atkins; Janice J Dutcher; Daniel J George; Kim A Margolin; Robert S DiPaola
Journal: J Clin Oncol Date: 2015-06-15 Impact factor: 44.544

Review 6. Sunitinib in the treatment of metastatic renal cell carcinoma.

Authors: Thomas A Schmid; Martin E Gore
Journal: Ther Adv Urol Date: 2016-08-23

Review 7. Combination therapy for renal cell cancer: what are possible options?

Authors: Napoleon Santos; Justin B Wenger; Pamela Havre; Yanxia Liu; Roi Dagan; Iman Imanirad; Alison M Ivey; Robert A Zlotecki; Chester B Algood; Scott M Gilbert; Carmen J Allegra; Paul Okunieff; Johannes Vieweg; Nam H Dang; Hendrik Luesch; Long H Dang
Journal: Oncology Date: 2011-11-12 Impact factor: 2.935

Review 8. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.

Authors: Sumanta Kumar Pal; Stephen Williams; David Y Josephson; Courtney Carmichael; Nicholas J Vogelzang; David I Quinn
Journal: Mol Cancer Ther Date: 2012-02-17 Impact factor: 6.261

Review 9. Safety and feasibility of targeted agent combinations in solid tumours.

Authors: Sook Ryun Park; Myrtle Davis; James H Doroshow; Shivaani Kummar
Journal: Nat Rev Clin Oncol Date: 2013-01-29 Impact factor: 66.675

10. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).

Authors: Jason Fangusaro; Sridharan Gururangan; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Katherine E Warren; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Larry E Kun; Maryam Fouladi
Journal: Cancer Date: 2013-09-19 Impact factor: 6.860